These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 2684039

  • 1. Prognostic importance of myelosuppression during maintenance treatment of lymphoblastic leukaemia. Leukaemia in Childhood Working Party of the Medical Research Council.
    Dolan G, Lilleyman JS, Richards SM.
    Arch Dis Child; 1989 Sep; 64(9):1231-4. PubMed ID: 2684039
    [Abstract] [Full Text] [Related]

  • 2. Medical Research Council leukaemia trial--UKALL V: an attempt to reduce the immunosuppressive effects of therapy in childhood acute lymphoblastic leukemia. Report to the Council by the Working Party on Leukaemia in Childhood.
    Chessells JM, Durrant J, Hardy RM, Richards S.
    J Clin Oncol; 1986 Dec; 4(12):1758-64. PubMed ID: 3537216
    [Abstract] [Full Text] [Related]

  • 3. Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood).
    Eden OB, Lilleyman JS, Richards S, Shaw MP, Peto J.
    Br J Haematol; 1991 Jun; 78(2):187-96. PubMed ID: 2064956
    [Abstract] [Full Text] [Related]

  • 4. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia.
    Chessells JM, Bailey C, Richards SM.
    Lancet; 1995 Jan 21; 345(8943):143-8. PubMed ID: 7823668
    [Abstract] [Full Text] [Related]

  • 5. Analysis of treatment in childhood leukaemia. I. Predisposition to methotrexate-induced neutropenia after craniospinal irradiation. Report to the Medical Research Council of the Working Party on Leukaemia in Childhood.
    Br Med J; 1975 Sep 06; 3(5983):563-6. PubMed ID: 1100179
    [Abstract] [Full Text] [Related]

  • 6. Medical Research Council leukaemia trial, UKALL VII. A report to the Council by the Working Party on Leukaemia in Childhood.
    Arch Dis Child; 1985 Nov 06; 60(11):1050-4. PubMed ID: 3907505
    [Abstract] [Full Text] [Related]

  • 7. Analysis of treatment in childhood leukaemia. II. Timing and the toxicity of combined 6-mercaptopurine and methotrexate maintenance therapy.
    MacLennan IC, Kay HE, Festenstein M, Smith PG.
    Br J Haematol; 1976 Jun 06; 33(2):179-88. PubMed ID: 1063593
    [Abstract] [Full Text] [Related]

  • 8. Continuing (maintenance) therapy in lymphoblastic leukaemia: lessons from MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia.
    Chessells JM, Harrison G, Lilleyman JS, Bailey CC, Richards SM.
    Br J Haematol; 1997 Sep 06; 98(4):945-51. PubMed ID: 9326194
    [Abstract] [Full Text] [Related]

  • 9. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
    Nielsen SN, Grell K, Nersting J, Abrahamsson J, Lund B, Kanerva J, Jónsson ÓG, Vaitkeviciene G, Pruunsild K, Hjalgrim LL, Schmiegelow K.
    Lancet Oncol; 2017 Apr 06; 18(4):515-524. PubMed ID: 28258828
    [Abstract] [Full Text] [Related]

  • 10. Intensive consolidation chemotherapy for acute lymphoblastic leukaemia (UKALL X pilot study).
    Pinkerton CR, Bowman A, Holtzel H, Chessells JM.
    Arch Dis Child; 1987 Jan 06; 62(1):12-8. PubMed ID: 3468886
    [Abstract] [Full Text] [Related]

  • 11. Improvement in treatment for children with acute lymphoblastic leukaemia. The Medical Research Council UKALL trials, 1972-84. Report to the Council by the Working Party on Leukaemia in Childhood.
    Lancet; 1986 Feb 22; 1(8478):408-11. PubMed ID: 2868339
    [Abstract] [Full Text] [Related]

  • 12. Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia.
    Lennard L, Rees CA, Lilleyman JS, Maddocks JL.
    Br J Clin Pharmacol; 1983 Oct 22; 16(4):359-63. PubMed ID: 6578834
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse.
    Schmiegelow K, Heyman M, Gustafsson G, Lausen B, Wesenberg F, Kristinsson J, Vettenranta K, Schroeder H, Forestier E, Rosthoej S, Nordic Society of Paediatric Haematology and Oncology (NOPHO).
    Leukemia; 2010 Apr 22; 24(4):715-20. PubMed ID: 20130603
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Excessive chemotherapy-related myelotoxicity in children with Down syndrome and acute lymphoblastic leukaemia.
    Blatt J, Albo V, Prin W, Orlando S, Wollman M.
    Lancet; 1986 Oct 18; 2(8512):914. PubMed ID: 2876340
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia.
    Clavell LA, Gelber RD, Cohen HJ, Hitchcock-Bryan S, Cassady JR, Tarbell NJ, Blattner SR, Tantravahi R, Leavitt P, Sallan SE.
    N Engl J Med; 1986 Sep 11; 315(11):657-63. PubMed ID: 2943992
    [Abstract] [Full Text] [Related]

  • 19. Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.
    Vang SI, Schmiegelow K, Frandsen T, Rosthøj S, Nersting J.
    Cancer Chemother Pharmacol; 2015 May 11; 75(5):1089-93. PubMed ID: 25788208
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.